Asgard Therapeutics AB, a privately held preclinical biotech, has appointed biopharma executive Cristina Csimma to its board and two immunologists to its advisory board, as the company advances its lead asset AT-108 towards clinical trials. The gene therapy reprogrammes tumour cells into a subset of dendritic cells to mount a personalised cytotoxic T cell response in cancer. The new board member brings expertise in venture capital and the US biotech capital market and is also on the board of Syncona, a UK investment group. The advisory board members are Ignacio Melero, who was appointed in 2023 as Kidani professor of cancer immuno-therapeutics at the University of Oxford, UK, and Brian Brown, who is vice chair of the department of immunology at the Mount Sinai Medical Center in New York, US.
Copyright 2025 Evernow Publishing